Wegovy and Vision Loss Risk: What Patients Need to Understand
The popular weight loss medication Wegovy (semaglutide) may carry a higher risk of a specific type of vision loss compared to other GLP-1 receptor agonists like Ozempic and Rybelsus, according to recent research. While the risk remains rare, understanding the potential connection is crucial for both patients and healthcare providers.
What is Ischemic Optic Neuropathy (ION)?
Ischemic optic neuropathy (ION) occurs when blood flow to the optic nerve is abruptly interrupted, leading to sudden vision loss. It’s a serious condition that can have lasting effects on eyesight.
The Recent Research Findings
A study published in the British Journal of Ophthalmology analyzed data from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) between 2017 and 2024. Researchers examined over 30 million reports and found that, although rare, the risk of ION was nearly five times higher in individuals using Wegovy compared to those using Ozempic. FDA.
The study also revealed a gender disparity, with men experiencing a three times higher risk of developing ION compared to women.
Why Wegovy May Pose a Higher Risk
Researchers hypothesize that the higher incidence of ION with Wegovy may be linked to its higher dosage and the speed of administration. Wegovy is an injectable formulation used specifically for weight loss, often administered at higher doses than medications like Ozempic and Rybelsus, which are primarily used for diabetes management. FDA.
The study suggests that the use of Wegovy at high doses “probably drives this stronger association by predisposing to optic nerve hypoperfusion through intravascular volume contraction and hypotension.” Though, a direct clinical link has not yet been established.
Oral Semaglutide and Vision Risk
Interestingly, Rybelsus, the oral form of semaglutide, did not show any reported cases of ION in the analysis. This suggests that the formulation – specifically, the slower absorption of the pill – may play a role in the risk profile. AJMC.
What Does This Mean for Patients?
These findings highlight a potential safety concern that warrants further investigation. While the absolute risk of ION remains low, individuals taking Wegovy should be aware of the potential symptoms, which include:
- Sudden vision loss
- Blurred vision
- Changes in color vision
- Pain with eye movement
If you experience any of these symptoms, it’s crucial to seek immediate medical attention from an ophthalmologist.
Expert Perspective
Independent experts in ophthalmology emphasize the need for further research, particularly given the increasing prevalence of obesity and the expanding use of these medications, including recent approvals for use in children as young as 12. General Medicine.
They also point to a growing body of medical literature documenting eye complications associated with anti-obesity drugs, underscoring the importance of careful monitoring and specialist evaluation.
Important Considerations
Wegovy, like other GLP-1 receptor agonists, works by mimicking a natural hormone that regulates appetite and calorie intake. Wegovy. It is prescribed alongside a reduced-calorie diet and increased physical activity to aid in weight loss and maintenance.
It’s important to remember that Wegovy should not be used in combination with other semaglutide-containing products or other GLP-1 receptor agonists. FDA.
Key Takeaways
- Wegovy may be associated with a higher risk of ischemic optic neuropathy (ION) compared to Ozempic and Rybelsus.
- The risk appears to be higher in men.
- The higher dosage and injectable formulation of Wegovy may contribute to the increased risk.
- Individuals taking Wegovy should be aware of the symptoms of ION and seek immediate medical attention if they experience any vision changes.
- Further research is needed to fully understand the connection between Wegovy and vision loss.